Drilldown: Medicines
Medicines > classes 
:
Sedative-Hypnotic or
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]]
:
Sedative-Hypnotic or
[[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]] Use the filters below to narrow your results.
generic:
Bromazolam (1) ·
Clonazolam (1) ·
Deschloroetizolam (1) ·
Diclazepam (1) ·
Doxazosin (1) ·
Dutasteride (1) ·
Estazolam (1) ·
Eszopiclone (1) ·
Ethchlorvynol (1) ·
Finasteride (1) ·
Flualprazolam (1) ·
Flubromazepam (1) ·
Flubromazolam (1) ·
Flunitrazepam (1) ·
Flunitrazolam (1) ·
Flurazepam (1) ·
Gaboxadol (1) ·
GHB (1) ·
Glutethimide (1) ·
Lormetazepam (1) ·
Methaqualone (1) ·
Midazolam (1) ·
Nifoxipam (1) ·
Nitrazepam (1) ·
Pentobarbital (1) ·
Quazepam (1) ·
Ramelteon (1) ·
Secobarbital (1) ·
Tamsulosin (1) ·
Tasimelteon (1) ·
Temazepam (1) ·
Terazosin (1) ·
Triazolam (1) ·
Zaleplon (1) ·
Zopiclone (1)
brand:
None (9) ·
(none, never marketed) (1) ·
Avodart; combined with tamsulosin as Jalyn (1) ·
Cardura, Cardura XL (1) ·
Dalmane (1) ·
Doral (1) ·
Doriden (1) ·
Flomax (1) ·
Halcion (1) ·
Hetlioz (1) ·
Hytrin (US brand discontinued); mostly generic (1) ·
Imovane (1) ·
Lunesta (1) ·
Mogadon (1) ·
Nembutal (1) ·
Placidyl (1) ·
Proscar (5 mg, BPH), Propecia (1 mg, alopecia) (1) ·
ProSom (1) ·
Quaalude (1) ·
Restoril (1) ·
Rohypnol (1) ·
Rozerem (1) ·
Seconal (1) ·
Sonata (1) ·
THIP (1) ·
Versed (1) ·
Xyrem (1)
classes: (Click arrow to add another value)
mechanism:
None (6) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator (15) ·
GABAA positive allosteric modulator (non-benzodiazepine) (3) ·
GABAA positive allosteric modulator; very long half-life (1) ·
GABAA potentiator (1) ·
GABAA potentiator and direct activator (2) ·
GABAB agonist; GHB receptor agonist (1) ·
Melatonin receptor agonist (2) ·
Positive allosteric modulator of the GABA<sub>A</sub> receptor at the benzodiazepine binding site; increases frequency of Cl<sup>−</sup> channel opening, producing anxiolytic, sedative, hypnotic, anticonvulsant, and skeletal-muscle relaxant effects. (1) ·
Selective GABAA agonist (extrasynaptic delta subunit) (1) ·
'"`UNIQ--vote-0000111B-QINU`"' Intraoperative floppy iris syndrome is a recognized class effect. Recently emerging evidence (observational) suggests possible Parkinson's disease risk reduction via PGK1 binding — investigational and not a clinical indication'"`UNIQ--ref-0000111C-QINU`"'. (1)
uses:
None (29) ·
No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) ·
'"`UNIQ--vote-000001BA-QINU`"', '"`UNIQ--vote-000001BB-QINU`"' (1) ·
'"`UNIQ--vote-0000052E-QINU`"', '"`UNIQ--vote-0000052F-QINU`"', '"`UNIQ--vote-00000530-QINU`"' (1) ·
'"`UNIQ--vote-00000AAD-QINU`"', '"`UNIQ--vote-00000AAE-QINU`"', '"`UNIQ--vote-00000AAF-QINU`"' (1) ·
'"`UNIQ--vote-00000D57-QINU`"', '"`UNIQ--vote-00000D58-QINU`"' (1) ·
'"`UNIQ--vote-0000111D-QINU`"', '"`UNIQ--vote-0000111E-QINU`"' (1)
starting dose:
None (29) ·
0.4 mg PO once daily, 30 minutes after the same meal each day (1) ·
0.5 mg PO once daily (1) ·
1 mg PO at bedtime to limit first-dose syncope; titrate weekly to 5-10 mg (1) ·
5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia (1) ·
IR 1 mg PO at bedtime, titrate weekly; XL 4-8 mg PO daily (1) ·
No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)
preparations:
fda max:
onset:
None (29) ·
BP and symptomatic LUTS improvement within 1-2 weeks (2) ·
BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months (1) ·
Prostate volume reduction over 6-12 months (1) ·
Symptom improvement within 1 week; peak effect at 4-6 weeks (1) ·
~20–40 min PO; faster sublingual/intranasal. (1)
duration:
halflife:
None (29) ·
9-15 hours'"`UNIQ--ref-000001BC-QINU`"' (1) ·
Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) ·
~12 hours'"`UNIQ--ref-0000111F-QINU`"' (1) ·
~22 hours'"`UNIQ--ref-00000AB0-QINU`"' (1) ·
~5 weeks (much longer than finasteride's ~6 hours)'"`UNIQ--ref-00000D59-QINU`"' (1) ·
~5-6 hours in young men, ~8 hours in elderly'"`UNIQ--ref-00000531-QINU`"' (1)
bioavailability:
None (29) ·
>90% (oral; food slows absorption and reduces peaks, hence the post-meal dosing rule)'"`UNIQ--ref-000001BD-QINU`"' (1) ·
>90% (oral; not significantly affected by food)'"`UNIQ--ref-00001120-QINU`"' (1) ·
Not formally characterized in humans. (1) ·
~60% (oral)'"`UNIQ--ref-00000D5A-QINU`"' (1) ·
~63% (oral)'"`UNIQ--ref-00000532-QINU`"' (1) ·
~65% (oral)'"`UNIQ--ref-00000AB1-QINU`"' (1)
pregnancy:
None (29) ·
'''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
'''Pregnant individuals should not handle dutasteride capsules''' (skin absorption risk through intact capsule); can cause hypospadias in male fetus.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; rarely indicated in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not applicable (male indication); historical Category B if used in unrelated female cases.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 35 results in range #1 to #35.